Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH. Miles Prince, M. D’Incan, Julia Scarisbrick et al.|The Lancet|2017Cited by 580
Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cellsMaria Corinna Palanca-Wessels, Oliver W. Press|Oncotarget|2016Cited by 49